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COMMENTARY
The hybrid AAVP tool gets an upgrade
Jo~ao Alves-Cruzeiroa,1, Christopher P. Webstera,1, and Mimoun Azzouza,2
Gene therapy is the use of nucleic acids as therapeutic
agents, with the purpose of restoring the expression of
a missing/nonfunctional gene, silencing the expression
of a mutant allele that has become toxic, or expressing
cytotoxic genes to induce apoptosis and kill rogue cells.
The last of the three is the main strategy used for cancer
gene therapy. One of the major hurdles of targeting
solid tumors for clinical translation, however, is the lack
of delivery vehicles capable of inducing a robust
expression of the transgene in the target population of
cells while keeping immunogenicity and off-target
effects to a minimum. While mammalian viruses have
been the most widely used due to their natural ability
to express foreign DNA or RNA in the nucleus of
infected cells, several publications have demonstrated
that hybrid prokaryotic–eukaryotic viral vectors can be
attractive vehicles, particularly for genetic-mediated
imaging and therapeutic intervention in tumor cells
(1). The hybrid adeno-associated virus (AAV)/phage
(AAVP) has been successfully used in several in vivo
models to target solid tumors with greater specificity,
facilitating positron emission tomography (PET) im-
aging and suppressing tumor growth by disrupting
tumor angiogenesis. In PNAS, Suwan et al. (2) increase
the versatility of AAVP by designing 2 phages capable
of avoiding nonspecific adsorption and escaping
endosomal-mediated degradation, significantly im-
proving the transduction outcome. This work not only
will have important implications for phage-mediated
cancer gene therapy but may also facilitate similar op-
timizations in other gene transfer vectors.
Over millions of years, viruses have evolved strate-
gies to introduce their viral genome into target cells,
subsequently hijacking the host’s cellular machinery
to replicate. In recent years, this has made them very
attractive for gene therapy applications, but the
choice between prokaryotic phage and mammalian
viruses needs to include careful consideration of each
vector’s advantages and disadvantages and their com-
patibility for a given application. Mammalian viruses
can be potent delivery vehicles for human cells and
are widely used in clinical trials worldwide, but their
in vivo use often results in nonspecific tissue transduc-
tion due to their native tropism and production costs
can be considerably high. On the other hand, prokary-
otic phages have evolved to specifically infect bacteria
and have no native tropism for mammalian targets,
meaning surface ligands can be adapted and engi-
neered to bind particular mammalian receptors,
targeting them to certain cell populations with great
specificity. Their use is considered safe in humans, and
their production method makes it cheaper for clinical
translation (3). This makes phage-based vector sys-
tems attractive for cancer gene therapy, where spec-
ificity is of the utmost importance. However, basic
phages also lack the necessary tools required for effi-
cient transgene expression in mammalian cells and are
therefore considered poor delivery vehicles.
To overcome the phages’ poor eukaryotic trans-
duction profile, Hajitou et al. (1) first developed the
hybrid virus AAVP over 10 y ago, consisting of a phage
coating structure capable of delivering an inverted
terminal repeats-flanked AAV transgene, which con-
ferred greater stability to the construct upon transduc-
tion and enhanced its expression efficiency. Using a
ligand that targets the tumor vasculature (RGD-4C)
inserted in the phage’s minor pIII coating proteins,
Hajitou et al. (1) demonstrated how systemic adminis-
tration of the RGD-4C AAVP selectively targeted tu-
mors in vivo. This system then allows the transfer of the
AAV transgene of choice, enabling bioluminescence
imaging and PET imaging and even inhibiting tumor
growth, depending on content of the transgene (1).
Despite these advances, the transduction efficiency of
target cells remained low when compared with some
mammalian viruses, mainly due to antibody neutrali-
zation and nonspecific adsorption by charged mole-
cules before transduction and endosomal-mediated
degradation of the viral particles once inside the cells
(Fig. 1A).
In PNAS, Suwan et al. (2) overcome these obstacles
by incorporating specific peptide sequences in the
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major pVIII coat proteins to confer degradation-resistance prop-
erties to the phages, while maintaining the RGD-4C targeting
ligand on the pIII minor coat protein, to direct these next-
generation particles to solid tumors cells. After demonstrating
that these peptides do not compromise the functionality of the
phage or its ability to transduce cells, Suwan et al. (2) introduced
the charged neutralizing sequence Ala-Lys-Ala-Ser (AKAS) in the
wild-type pVIII coating, conferring zwitterionic properties to the
virus. By incorporating this AKAS neutralizing peptide, the overall
charge of the phage was shifted toward neutrality, significantly
decreasing the nonspecific adsorption by fibrinogen and promot-
ing its escape from a neutralizing antibody, resulting in enhanced
tumor cell transduction (Fig. 1B).
Upon entry of the viral particles into the intracellular space,
endosomal-mediated degradation poses another significant bar-
rier to efficient transduction. To create enhanced phages with the
ability to bypass this obstacle, Suwan et al. (2) selected 3 different
peptide sequences that could promote endosomal escape and
introduced them in the rpVIII gene. The histidine-rich H5WYG
peptide was found to confer buffering properties to the phage
while encapsulated in endosomes, likely resulting in increased os-
motic swelling of the endosome, destabilization, and release of the
phages to the cytoplasm (Fig. 1C). This next-generation RGD4C-
H5WYG-AAVP containing the luciferase reporter gene was shown
to have markedly improved transduction efficiency at different viral
concentrations when compared with phages without this peptide
and was able to promote targeted gene delivery in cancer cell lines.
Importantly, Suwan et al. (2) utilized bafilomycin A1, an inhibitor of
the vacuolar ATPase proton pump, to prevent endosomal proton-
ation, and convincingly show that the increased transduction effi-
ciency is indeed due to endosomal escape.
Suwan et al. (2) also show that RGD4C-H5WYG-AAVP was able
to express luciferase in tumors in vivo and did so more efficiently
than standard RGD4C-AAVP, with up to 3.5-fold higher expres-
sion. In the future, it will be interesting to see how this enhanced
targeted gene delivery can be weaponized to inhibit tumor
growth or to facilitate PET imaging applications. Finally, since
Suwan et al. (2) demonstrate that a multifunctional hybrid AAVP
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Fig. 1. Next-generation AAVP phages can overcome pre- and postinternalization barriers to transduction. (A) The original RGD4C-AAVP can
transduce mammalian cells, although its efficiency is reduced due to antibody neutralization and endosomal-mediated degradation. (B)
Introduction of the AKAS peptide into the pVIII phage coating reduces nonspecific adsorption and neutralization by antibodies, increasing the
transduction efficiency. (C) When expressed in the rpVIII coat protein, the histidine-rich H5WYG peptide promotes endosomal escape of the
AAVP, decreasing endosomal-mediated degradation and enhancing transduction.
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with both a wild-type and a recombinant pVIII is viable, a single
phage expressing both the AKAS neutralizing peptide and the
H5WYG endosomal escape peptide becomes theoretically possi-
ble and, if functional, could potentially combine the enhancing
properties of both peptides.
These studies by Suwan et al. (2) improve the versatility and
power of the AAVP tool, but they also hold promise for optimiza-
tion of other vectors, with even broader applications. Indeed,
antibody-mediated neutralization and endosomal and ubiquitin–
proteasome-mediated degradation are also key barriers for trans-
duction by AAV viruses, one of the most widely used gene therapy
vehicles for noncancer applications (4–6). Strategies to overcome
this have included mutagenesis of specific regions of the capsid
(7, 8) or the use of capsid decoys combined with therapeutic AAV
(9). One can hypothesize that the modifications reported by
Suwan et al. (2) might be suitable candidates for similar optimiza-
tions in AAV, since their efficacy has already been established in a
viral transduction setting. Of course, caution will be needed to
ensure the immunogenicity of any such engineered viruses re-
mains low, but these studies open up the possibility of engineer-
ing viral strains with a narrower tissue tropism, reduced off targets,
and therefore more specific and efficient gene delivery.
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